3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasms
2
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hyperlipoproteinemia Type II
1
Hematologic Neoplasms
1
Hemangioma, Cavernous, Central Nervous System
1
Hearing Loss
1
Head and Neck Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Cardiotoxicity
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
69
Nivolumab
69
cabozantinib
45
Ipilimumab
38
Specimen Handling
33
Magnetic Resonance Spectroscopy
33
lenvatinib
26
Axitinib
25
belzutifan
21
Sunitinib
18
Biopsy
15
Radiosurgery
14
CTLA-4 Antigen
13
atezolizumab
12
Everolimus
10
pazopanib
8
fludarabine
8
avelumab
8
Bevacizumab
8
toripalimab
7
cemiplimab
7
Nephrectomy
7
Immunoglobulin G
7
Cyclophosphamide
7
aldesleukin
6
Standard of Care
6
Radiotherapy
6
Blood Specimen Collection
6
spartalizumab
5
palbociclib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Atorvastatin
×
1 year
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled